Inflammatory	B-DISEASE
bowel	I-DISEASE
disease	I-DISEASE
patients	O
exhibited	O
increased	O
mucosal	B-PROCESS
permeability	I-PROCESS
and	O
enhanced	O
dendritic	B-PROCESS
cell	I-PROCESS
antigen	I-PROCESS
presentation.	I-PROCESS

Allergic	B-PROCESS
reactions	I-PROCESS
involved	O
enhanced	O
mast	B-PROCESS
cell	I-PROCESS
degranulation	I-PROCESS
and	O
increased	B-PROCESS
histamine	I-PROCESS
release	I-PROCESS
into	
systemic	O
circulation.	O

The	O
biologics	B-PROCESS
therapy	I-PROCESS
targeted	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor-alpha	I-CHEMICAL
while	O
preserving	O
adaptive	O
immune	B-PROCESS
memory	I-PROCESS
responses.	I-PROCESS

Autoimmune	B-DISEASE
hepatitis	I-DISEASE
patients	O
demonstrated	O
increased	O
plasma	B-PROCESS
cell	I-PROCESS
infiltration	I-PROCESS
and	O
elevated	O
immunoglobulin	B-PROCESS
G	I-PROCESS
autoantibody	I-PROCESS
production.	I-PROCESS

Psoriasis	B-DISEASE
development	O
involved	O
enhanced	O
keratinocyte	B-PROCESS
proliferation	I-PROCESS
and	O
increased	O
interleukin-17	B-CHEMICAL
inflammatory	B-PROCESS
pathway	I-PROCESS
activation.	I-PROCESS

Systemic	B-DISEASE
sclerosis	I-DISEASE
patients	O
showed	O
increased	O
collagen	B-PROCESS
synthesis	I-PROCESS
and	O
enhanced	O
transforming	B-PROCESS
growth  I-PROCESS
factor-beta	I-PROCESS
signaling	I-PROCESS
pathways.	I-PROCESS

Atopic	B-DISEASE
dermatitis	I-DISEASE
severity	O
correlated	O
with	O
elevated	O
thymic	B-CHEMICAL
stromal	I-CHEMICAL
lymphopoietin	I-CHEMICAL
levels	O
and	O
impaired	B-PROCESS
skin	I-PROCESS
barrier	I-PROCESS
function.	I-PROCESS

The	O
checkpoint	B-PROCESS
inhibitor	I-PROCESS
therapy	I-PROCESS
enhanced	O
T-cell	B-PROCESS
activation	I-PROCESS
while	O
reducing	O
programmed	B-PROCESS
death-1	I-PROCESS
immune	I-PROCESS
suppression.	I-PROCESS

Sj√∂grens	B-DISEASE
syndrome	I-DISEASE
patients	O
exhibited	O
increased	O
B-cell	B-PROCESS
activation	I-PROCESS
and	O
elevated	O
rheumatoid	B-PROCESS
factor	I-PROCESS
autoantibody	I-PROCESS
production.	I-PROCESS

Inflammatory	B-DISEASE
arthritis	I-DISEASE
involved	O
enhanced	O
synovial	B-PROCESS
fluid	I-PROCESS
accumulation	I-PROCESS
and	O
increased	O
prostaglandin	B-PROCESS
inflammatory	I-PROCESS
mediator	I-PROCESS
synthesis.	I-PROCESS

The	O
targeted	B-PROCESS
therapy	I-PROCESS
reduced	O
interleukin-6	B-PROCESS
receptor	I-PROCESS
signaling	I-PROCESS
while	O
preserving	O
essential	O
immune	B-PROCESS
homeostasis	I-PROCESS
mechanisms.	I-PROCESS

Vasculitis	B-DISEASE
patients	O
demonstrated	O
increased	O
endothelial	B-PROCESS
cell	I-PROCESS
activation	I-PROCESS
and	O
enhanced	O
complement-mediated	B-PROCESS
tissue	I-PROCESS
damage.	I-PROCESS

Celiac	B-DISEASE
disease	I-DISEASE
triggered	O
enhanced	O
tissue	B-PROCESS
transglutaminase	I-PROCESS
expression	I-PROCESS
and	O
increased	O
anti-gliadin	B-PROCESS
antibody    I-PROCESS
production.	I-PROCESS

The	O
anti-cytokine	B-PROCESS
treatment	I-PROCESS
reduced	O
inflammatory	B-PROCESS
cascade	I-PROCESS
amplification	I-PROCESS
while	O
maintaining	O
protective	O
innate	B-PROCESS
immunity	I-PROCESS
responses.	I-PROCESS

Systemic	B-DISEASE
mastocytosis	I-DISEASE
patients	O
showed	O
increased	O
tryptase	B-PROCESS
enzyme	I-PROCESS
release	I-PROCESS
and	O
enhanced	O
IgE-mediated	B-PROCESS
allergic	I-PROCESS
reactions.	I-PROCESS

Graft-versus-host	B-DISEASE
disease	I-DISEASE
involved	O
enhanced	O
donor	O
T-cell	B-PROCESS
activation	I-PROCESS
and	O
increased	O
inflammatory	B-PROCESS
tissue	I-PROCESS
infiltration	I-PROCESS
processes.	I-PROCESS